Can the host immune response against SARS-CoV2 also cause an anticancer effect?

Kahraman, Seda; Akinci, Muhammed Bulent; Sendur, Mehmet Ali Nahit; Yalcin, Bulent

Kahraman, Seda; Akinci, Muhammed Bulent; Sendur, Mehmet Ali Nahit; Yalcin, Bulent.

Afiliação

Kahraman S; Faculty of Medicine, Department of Medical Oncology, Ankara City Hospital, Ankara Yildirim Beyazit University, Üniversiteler Mahallesi Bilkent Cad. No: 1 Çankaya, 06800, Ankara, Turkey. sedakayacan.kahraman@gmail.com.
Akinci MB; Faculty of Medicine, Department of Medical Oncology, Ankara City Hospital, Ankara Yildirim Beyazit University, Üniversiteler Mahallesi Bilkent Cad. No: 1 Çankaya, 06800, Ankara, Turkey.
Sendur MAN; Faculty of Medicine, Department of Medical Oncology, Ankara City Hospital, Ankara Yildirim Beyazit University, Üniversiteler Mahallesi Bilkent Cad. No: 1 Çankaya, 06800, Ankara, Turkey.
Yalcin B; Faculty of Medicine, Department of Medical Oncology, Ankara City Hospital, Ankara Yildirim Beyazit University, Üniversiteler Mahallesi Bilkent Cad. No: 1 Çankaya, 06800, Ankara, Turkey.

Med Oncol ; 38(8): 90, 2021 Jun 30.

Article em En | MEDLINE | ID: mdl-34191146

Assuntos

COVID-19/imunologia; Neoplasias/imunologia; SARS-CoV-2/imunologia; Reações Cruzadas; Citocinas/imunologia; Humanos; Inibidores de Checkpoint Imunológico/imunologia; Ativação Linfocitária; Linfócitos T/imunologia; Microambiente Tumoral/imunologia

Palavras-chave

COVID-19 disease; Immune checkpoint blockage effect; Tumor immune responses; Tumor microenvironment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google